Strata Critical Medical, Inc. 8-K

What Happened
Strata Critical Medical, Inc. (SRTA) filed an 8-K on June 3, 2026 reporting the final voting results from its May 28, 2026 annual meeting of stockholders (proxy initially filed April 14, 2026). Two Class II directors were elected to serve until the 2029 annual meeting, Deloitte & Touche LLP was ratified as the company's independent registered public accounting firm for fiscal 2026, and the company’s advisory "Say-on-Pay" vote on executive compensation was approved.

Key Details

• Director elections (terms through the 2029 annual meeting):
  • William A. Heyburn — For: 46,050,902; Withhold: 505,421; Broker non-votes: 12,687,496.
  • Andrew Lauck — For: 39,525,159; Withhold: 7,031,164; Broker non-votes: 12,687,496.
• Auditor ratification (fiscal year ending Dec 31, 2026): Deloitte & Touche LLP — For: 58,946,832; Against: 65,815; Abstain: 231,172.
• Advisory "Say-on-Pay" (non-binding) — For: 38,497,962; Against: 8,022,682; Abstain: 35,679; Broker non-votes: 12,687,496.
• Report signed by William A. Heyburn (Co‑Chief Executive Officer and Chief Financial Officer) on June 3, 2026.

Why It Matters

• Board continuity: The election of the two Class II directors locks in the current board composition for the next several years (until the 2029 annual meeting), which affects oversight and strategic direction.
• Audit continuity: Ratification of Deloitte & Touche LLP maintains the company’s current auditor relationship for 2026, affecting financial reporting and audit continuity.
• Executive pay approval: The advisory approval of executive compensation indicates majority shareholder support for the named executive officers’ pay packages, though the vote is non‑binding.

Investors should note the presence of substantial broker non‑votes on director and say‑on‑pay items (12,687,496 shares), which reflects shares held by brokers that did not vote on those proposals and can affect the vote totals for contested or advisory matters.